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ABSTRACT Proper control of the mammalian cell cycle
requires the function of cyclin-dependent kinase (CDK) in-
hibitors. The p21 family currently includes three distinct
genes, p21, p27Kip1, and p57Kip2, that share a common N-
terminal domain for binding to and inhibiting the kinase
activity of CDK-cyclin complexes. The p21 protein also binds
to proliferating cell nuclear antigen (PCNA) through a sep-
arate C-terminal domain affecting DNA replication and re-
pair. The p27 and p57 proteins also each contain unique
C-terminal domains whose functions are unknown. Here we
show that the human p57 protein, like p21, contains a
PCNA-binding domain within its C terminus that, when
separated from its N-terminal CDK-cyclin binding domain,
can prevent DNA replication in vitro and S phase entry in vivo.
Disruption of either CDKycyclin or PCNA binding partially
reduced p57’s ability to suppress mycyRAS-mediated trans-
formation in primary cells, while loss of both inhibitory
functions completely eliminated p57’s suppressive activity.
Thus, control of cell cycle and suppression of cell transfor-
mation by p57 require both CDK and PCNA inhibitory
activity, and disruption of either or both functions may lead
to uncontrolled cell growth.
The primary control of the eukaryotic cell cycle is provided by
the activity of a family of serineythreonine protein kinases,
cyclin-dependent kinases (CDKs) (1). The enzymatic activity
of a CDK can be positively regulated by the binding of a cyclin
and negatively regulated by the binding of a CDK inhibitor. In
mammalian cells, there exists at least two distinct families of
CDK inhibitors, represented by the two prototypic CDK
inhibitors p16 and p21 (2). The p16yINK4 family of CDK
inhibitors currently includes three additional genes: p15INK4b,
p18INK4c, and p19INK4d (2). Members of the INK4 gene family
are related in sequence and evolution and specifically bind in
a binary fashion to two closely related CDK proteins, CDK4
and CDK6, thus suppressing cell growth in a pRb-dependent
manner (3). In contrast, the p21 family that currently contains
two other genes, p27Kip1 and p57Kip2, broadly inhibits CDK
activity by forming a ternary complex with the CDK and the
cyclin. A unique feature of CDK inhibitors is that their
expression can be induced by or is correlated with a wide range
of cell growth inhibitory signals, that include mitogen starva-
tion, cell-cell contact inhibition, DNA damage, antiprolifera-
tive cytokine treatment, terminal cell differentiation, and
cellular senescence (2, 3).
p21, initially identified in normal human fibroblasts as a
component of quaternary cyclin D-CDK complexes that also
contain proliferating cell nuclear antigen (PCNA), was sub-
sequently found to contain two separate binding activities: a
CDK-cyclin binding domain at the N terminus and a C-
terminally located PCNA binding site, respectively (reviewed
in ref. 2). Two additional members of the p21 family, p27 and
p57 share with p21 a common N-terminal domain for binding
to a wide range of CDK-cyclin complexes. The p27 and p57
proteins each contain a unique C-terminal domain known as
the QT domain, and p57 additionally contains a central PAPA
repeat (4, 5). The functions of the PAPA repeat and the QT
domain are unknown.
The p57 gene is located on human chromosome 11p15.5 (5),
a region predicted to contain a tumor suppressor gene(s)
involved in the development of several human cancers, includ-
ing those of the breast, bladder, lung, ovary, kidney, and
testicle (6). In particular, the gene for Beckwith–Wiedemann
syndrome (BWS) is localized in the 11p15.5 as determined by
the linkage analysis of autosomal dominant pedigrees. BWS is
characterized by numerous growth abnormalities and an in-
creased risk of childhood tumors. Specific loss of the maternal
11p15 allele and uniparental disomy (paternal) suggest that the
BWS gene is genomically imprinted, and the p57 gene is
maternally expressed and imprinted in both human and mouse
(7, 8). Consistent with its suggested role in tumor growth
suppression, mice lacking p57 function displayed altered cell
proliferation and differentiation, increased apoptosis and phe-
notypes seen in patients with BWS (9, 10). More direct
evidence for the involvement of the p57 gene in human cancer
was obtained by the finding that four of 24 (17%) BWS patients
examined contain mutations in the p57 gene that altered the
structure of the p57 protein (11, 12). Intriguingly, of the p57
mutations identified, three retained the N-terminal CDK-
cyclin binding domain: one lost the central PAPA repeat and
C-terminal domain, and two contained deletions in the C-
terminal QT domain. These findings strongly implicate a
separate activity located in the C terminus of p57 whose
disruption may contribute to altered cell growth control. In
this report, we demonstrate that human p57 contains a PCNA-
binding domain in this region that may result in such an
alteration.
MATERIALS AND METHODS
p57 Constructs. For the yeast two-hybrid screen, a C-
terminal cDNA fragment containing the C-terminal 55 amino
acid residues of human p27 (codons 142–198) and the C-
terminal 79 residues of human p57 (codons 236–316) were
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generated by PCR and inserted into pGBT8 as a fusion protein
with the DNA-binding domain of Gal4p (amino acids 1–147).
Yeast two-hybrid screening was conducted in a human WI-38
fibroblasts cDNA library following the manufacturer’s instruc-
tion (CLONTECH). We estimate that '5 3 106 transformants
were screened. Various human p57 mutants were generated by
oligonucleotide-mediated mutagenesis by using either Quick-
Change (Stratagene) or direct ligation and were verified by
DNA sequencing. Individual PCNA binding mutants are listed
(see Fig. 2). The CDKycyclin binding mutant used in cell
transformation assays (p57CKmut) contains two substitutions
(R31A and F34D) in the cyclin binding domain and two
(W61A and F65D) in the CDK binding region. Wild-type and
mutant p57 genes were placed under the control of a cyto-
megalovirus promoter for the analysis of cell cycle arrest
(pcDNA3, Invitrogen) or inserted in the pVNic retroviral
vector for the cell transformation assay (13). Expression of
each protein was first verified by in vitro translation in a TNT
rabbit reticulocyte lysate system (Promega). Expression of
each mutant protein in vivo and loss of CDK and cyclin binding
activity in p57CKmut was confirmed by coupled immunopre-
cipitation and Western blot analysis following cotransfection
of pVNic-p57CKmut and pCMV-cyclin D1 or pCMV-CDK2
into Saos-2 cells (confirmatory results not shown).
Peptides, Antibodies, and Protein Expression. All peptides
were purified through HPLC and characterized on a mass
spectrometer. A rabbit polyclonal antibody specific to p57 was
generated by using a synthetic peptide derived from the human
p57 C terminus (GVGSVEQTPRKRLR). This antibody cross
reacts efficiently with mouse p57. The monoclonal anti-PCNA
antibody (PC10) was purchased from PharMingen. Histidine-
tagged proteins, the C terminus of human p57 (the last 79
residues), mouse p57 (the last 53 residues), human p27 (the last
55 residues), and full-length human p21 and p57, were purified
following the manufacturer’s instruction (Qiagen, Chatsworth,
CA). For the production of glutathione S-transferase (GST)
fusion proteins, the C termini of human p21 (the last 63
residues) and human p57 (the last 79 residues) were fused with
GST and purified by using glutathione Sepharose 4B (Phar-
macia). Recombinant baculoviruses expressing hexahistidine
tagged C-terminal p57 were constructed by using the pVL1393
baculovirus transfer vector (PharMingen). Other recombinant
baculoviruses have been described (5, 14). Procedures for
metabolic labeling and immunoprecipitations were as de-
scribed (14, 15).
In Vitro Binding Assays. The histidine-tagged proteins (1
mg) attached to a Ni-nitrilotriacetate (NTA) resin were mixed
with purified PCNA in 200 ml of Nonidet P-40 buffer (15) for
1 h at 4°C. The Ni-NTA resins were washed three times with
1 ml of Nonidet P-40 buffer containing 50 mM imidazole. For
in vitro competition assays (Fig. 2B), 20 ml of 35S-labeled
PCNA produced by using the reticulocyte in vitro transcrip-
tion-translation system was incubated with the p21 or p57
derived peptides for 30 min at room temperature, then added
to 200 ml Nonidet P-40 buffer containing 2 mg GST-p57C or
GST-p21C fusion proteins attached to glutathione-agarose
beads. The beads were incubated for 1 h at 4°C, then washed
three times with 1 ml of Nonidet P-40 buffer. Bound proteins
were released by boiling in SDS sample buffer, and electro-
phoresed on 15% denaturing polyacrylamide gels followed by
autoradiography.
DNA Replication Assays. Reaction mixtures (10 ml), assem-
bled at 0°C, contained 40 mM TriszHCl, pH 7.5; 0.5 mM DTT;
1 mg of BSA; 7 mM magnesium acetate; 2 mM ATP; 100 mM
each of dATP, dGTP, and dTTP; 20 mM [a-32P]dCTP (17, 100
cpmypmol); 8.7 fmol of singly-primed M13 DNA; 240 ng of
human single-stranded DNA binding protein; 100 fmol of
human RFC; 0.1 unit of human pol d and either 5 or 50 ng of
human PCNA, as indicated. Where specified, inhibitors were
added to reaction mixtures lacking RFC and pol d, and
reactions were incubated for 10 min at 0°C. RFC and pol d were
then added and reactions were incubated at 37°C for 30 min.
The amount of acid-insoluble material formed was determined
with an aliquot (1 ml) after termination with 20 mM EDTA.
Loading dye was added, and the mixtures were subjected to
agarose gel electrophoresis in buffer containing 30 mM NaOH
and 1 mM EDTA for 16 h at 35 V. Gels were dried and
autoradiographed for 1 h at 280°C.
Cell Culture, Transfection, Fluorescence-Activated Cell
Sorter Analysis, and Transformation Assay. Mammalian cells
were cultured in a 37°C incubator with 5% CO2 in DMEM
supplemented with 10% fetal bovine serum. Sf9 cells were
cultured in Grace’s medium supplemented with 10% heat-
inactivated fetal bovine serum at 27°C. Cell transfections were
carried out by using the Lipofectamine reagent according to
the manufacturer’s instructions (GIBCOyBRL). For cell cycle
inhibition analysis, Saos-2 cells at 20–30% confluence were
cotransfected with 10 mg of individual plasmids and 1 mg of
pcDNA3-GFP. Forty hours posttransfection, cells were har-
vested with trypsin, washed with PBS, then fixed in 5 ml of PBS
containing 3.6% paraformaldehyde for 30 min at 4°C. After
washing cells once with PBS containing 1% BSA, the DNA was
stained with propidium iodide (50 mgyml) containing 250
mgyml ribonuclease A and 0.1% Triton X-100. Flow cytometry
analysis was conducted by using a Becton Dickinson FACScan.
DNA content in 10,000 green fluorescent protein (GFP)-
positive cells is presented in the DNA histograms. Preparation
of early passage rat embryo fibroblast and transfection by the
calcium phosphate precipitation were described in (16). 0.8 3
106 rat embryo fibroblasts were seeded and transfected the
following day by the standard calcium-phosphate method with
DNA mixtures containing 30 mg of genomic carrier DNA and
2 mg each of the myc, ras, and indicated p57 expression
constructs or empty vector. The foci were verified as trans-
formed by microscopic inspection and counted 8 and 12 days
after transfection. The cells were then fixed and stained with
Giemsa for photographic documentation.
RESULTS
Human p57 Interacts with PCNA. To identify potential
biological activities located outside of the CDK-cyclin binding
domains of p27 and p57, we searched for cellular proteins that
could interact with the C-terminal portion of either protein by
using the yeast two-hybrid assay. A 250-bp fragment encoding
the 79 C-terminal amino acid residues of human p57 (hereafter
referred to as p57C) or a 171 bp fragment encoding the 55
C-terminal amino acid residues of human p27 (p27C) was
fused to the yeast Gal4 DNA binding domain. The resulting
vectors were cotransformed into yeast HF7c cells with a human
WI-38 fibroblasts cDNA library. No positive clones were
identified from the screen by using p27C (V. Coffield III and
Y.X., unpublished data). Of an estimated 5 3 106 transfor-
mants screened by using the C-terminal region of human p57,
four clones were obtained that were both His1 and positive for
b-galactosidase staining (Fig. 1A and data not shown). Se-
quencing analysis revealed that two independent clones en-
coded human PCNA (data not shown). Both were fused
in-frame with the GAL4 DNA activation domain, one starting
at amino acid residue 2 and the other containing an additional
17 bp of 59 untranslated region (59 UTR). To confirm the
interaction between p57C and the PCNA protein in a cell-free
system, purified recombinant fusion proteins containing six
copies of a histidine tag fused either to the C-terminal domain
of human p57 (His-p57C, Fig. 1B, lane 1), mouse p57[His-p57C
(Mm), lane 2], human p27 (His-p27C, lane 3), full-length
human p57 (His-p57, lane 4), or full-length human p21 (p21-
His, lane 5) were incubated with purified human PCNA
protein and then recovered on nickel-agarose beads. The
bound proteins were separated by SDSyPAGE and visualized
Biochemistry: Watanabe et al. Proc. Natl. Acad. Sci. USA 95 (1998) 1393
by Coomassie blue staining (Fig. 1B). Both the full-length and
the C-terminal region of human p57, as well as the full-length
human p21 protein bound PCNA at approximately a one-to-
one molar ratio. The C-terminal domain of mouse p57 con-
taining the last 53 residues did not bind a detectable amount
of PCNA (lane 2), and full-length mouse p57 produced by
baculoviruses in insect cells also exhibited a much weaker
PCNA binding activity than human p57 (data not shown).
Whether there exists a significant species difference between
p57 proteins in their PCNA binding activity remains to be
determined. In two separate assays involving the yeast two-
hybrid system and in vitro binding, we did not detect any
physical interaction between human p27 (either the C-terminal
domain or full-length protein), and PCNA (lane 3, and addi-
tional negative data not shown). To further confirm the
p57-PCNA interaction, Sf9 insect cells, were coinfected with
baculoviruses expressing individual proteins in various com-
binations, infected cells were metabolically labeled with [35S]-
methionine, and protein complexes were either recovered on
Ni-agarose or by immunoprecipitation and subsequently ana-
lyzed by SDSyPAGE. Both full-length p57 and the p57 C-
terminal domain formed stable binary complexes with PCNA
in vivo (Fig. 1C).
We examined whether p57, like p21, can also form quater-
nary complexes with CDKs, cyclins and PCNA (14). Quater-
nary cyclin D1-CDK4-p21-PCNA complexes can be recovered
by both anti-cyclin D1 and anti-CDK4 immunoprecipitation
(Fig. 1D, lanes 6 and 12). In contrast, repeated attempts failed
to detect p57 in either anti-cyclin D1 or anti-CDK4 immuno-
complexes, indicating the lack of formation of the quaternary
cyclin D1-CDK4-p57-PCNA complex (lanes 5 and 11, and data
not shown). In addition, we noticed that the small amount of
PCNA in anti-cyclin D1 immunocomplexes (lane 10), presum-
ably due to either direct interaction between cyclin D1 and
PCNA andyor an endogenously expressed p21-like protein in
Sf9 cells, was diminished by the expression of p57 (lane 11).
These observations suggest that, unlike p21, p57 may interact
with CDKycyclin and PCNA in a mutually exclusive manner.
The PCNA binding domain of p21 has been localized to a
small region spanning about 20 amino acid residues in the C
terminus as analyzed by mutagenesis (17–19). A 20 amino acid
region in human p57, but not mouse p57, or mouse and human
p27, contains significant similarity (four identical and eight
conserved residues) to the PCNA binding domain of p21 (Fig.
2A). This prompted us to determine if human p57 binds to
PCNA through this sequence. Equal amounts of fusion pro-
teins consisting of GST and the C-terminal domain of either
human p57 (GST-p57C) or p21 (GST-p21C) were incubated
with in vitro translated, 35S-labeled PCNA in the presence of
various p21 or p57 synthetic peptides. GST fusion proteins
were recovered on glutathione-agarose beads, and the bound
PCNA protein was analyzed by SDS-PAGE. An excess amount
of both GST-p21C and GST-p57C bound nearly all the input
PCNA in the absence of a competing peptide (Fig. 2B, lanes
FIG. 1. Interaction of human p57 with PCNA. (A) Yeast HF7c cells
were simultaneously transformed with a plasmid expressing a GAL4bd
fusion protein and a plasmid expressing a GAL4ad fusion protein as
indicated. Cells were streaked on nonselective medium with histidine
(-Leu, -Trp), selective medium without histidine (-Leu, -Trp, -His),
and selective medium without histidine but containing 5 mM 3-amino-
1,2, 3-triazole (-Leu, -Trp, -His, 3-AT). Staining for b-galactosidase
expression, activated from an independent GAL4 responsive pro-
moter, is shown (b-gal, Lower Right). The C-terminal domain of p21
possesses as a trans-activating activity (self-activation) when expressed
as a fusion protein with the GAL4 DNA binding domain. (B) Equal
amounts of histidine-tagged human p57C (lane 1), mouse p57 (lane 2),
human p27 (lane 3), full-length human p57 (lane 4), or human p21
(lane 5) were incubated with 2 mg purified human PCNA protein.
Mixtures were recovered on Ni-Sepharose beads, resolved by SDSy
PAGE, and stained with Coomassie blue. (C) Exponentially growing
Sf9 cells were singly infected with baculoviruses expressing the histi-
dine-tagged C-terminal domain of human p57 (His-p57C), full-length
human p57 (hp57), human PCNA, or doubly infected with their
combinations as indicated on the top of each lane. Cells were
metabolically labeled with [35S]methionine 40 h postinfection and p57
protein complexes were recovered on Ni-Sepharose or immunopre-
cipitated with an anti-p57 antibody and analyzed by SDSyPAGE and
autoradiography. (D) Exponentially growing Sf9 cells were coinfected
with baculoviruses expressing various human proteins. CDK4 and
cyclin D1 protein complexes were immunoprecipitated with indicated
antibodies and analyzed by SDSyPAGE and autoradiography.
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1 and 4). Addition of a molar excess of wild-type p21 peptide
containing the PCNA binding region (residues 139–160, lane
2), but not an amino terminal p21 peptide (residues 27–41,
lane 3), completely blocked the binding of GST-p57C to
PCNA. Conversely, a p57 peptide corresponding to the se-
quence similar to the PCNA binding domain of p21 (residues
263–285, lanes 5 and 6), but not a p57 peptide outside the
conserved region (lane 7), inhibited the binding of GST-p21C
to PCNA. Ten-fold more p57 peptide was necessary to com-
pletely block the binding of GST-p21C to PCNA as compared
with the amount of the p21 peptide necessary to block the
binding of GST-p57C to PCNA (compare lanes 5 and 6 with
lane 2). This indicates that p57 binds to PCNA with an affinity
that is at least 10-fold lower than p21.
An eight-amino acid motif (144QTSMTDFY151) in the 20-
amino acid region, in particular Met-147 and Phe-150, is
critical for p21 to bind PCNA (18). At these positions, human
p57 contains a conserved leucine (L271) and an identical
phenylalanine (F275) residue, respectively. Substitution of
either residue with an alanine or valine significantly reduced
PCNA binding. Mutation of both residues almost completely
abolished the binding of p57 to PCNA even when a large excess
was incubated with PCNA (Fig. 2C, lane 5). Mutation of either
residue also rendered p57 inactive in binding PCNA in vivo as
determined by the yeast two-hybrid assay (Fig. 2D). In addi-
tion, a truncated p57 protein (BWS8) that has lost 41 C-
terminal residues as the result of a T to AG transversiony
addition at codon 276 found in BWS exhibited no detectable
PCNA binding activity (data not shown). These results indicate
that p21 and p57 interact with PCNA via a similar mechanism
that involves a conserved region located at the C terminus of
both proteins.
C-Terminal Domain of p57 Inhibits PCNA-Dependent DNA
Synthesis. PCNA is essential for rapid and processive synthesis
of DNA by DNA polymerases d and «. The C-terminal domain
of p21 possesses a potent inhibitory activity on DNA synthesis
that can be reversed by increasing the level of PCNA (20–22).
In the presence of limiting levels of PCNA (5 ng, 17 mM
monomer), increasing amounts of p57C (His-p57C) or a
chemically synthesized p57 peptide (residues 263 to 285)
markedly inhibited nucleotide incorporation in the elongation
of singly-primed M13 DNA in a pol d holoenzyme reaction,
reaching 50% reduction in the presence of 20 mM and 10 mM
quantities of these two derivatives, respectively (Fig. 3B).
Consistent with its higher affinity in binding to PCNA, both
full-length p21 protein and a p21 peptide (residues 139–160)
were more effective inhibitors: 50% inhibition was observed
with 0.05 to 0.1 mM (Fig. 3A). The influence of the inhibitors
on the lengths of the DNA products formed in the pol d
holoenzyme catalyzed reaction was examined by alkaline
agarose gel electrophoresis. Both purified p57C (His-p57C,
Fig. 3C, lanes 5–8) and the p57 peptide (residues 263–285,
lanes 9–12) reduced the sizes of the DNA synthesis products.
Similar but more potent inhibition was observed with purified
p21 (lanes 2–4) and the p21 peptide (lanes 13 and 14). When
the level of PCNA added to the reactions was increased
10-fold, the lengths of the products produced in the presence
of 6.6 mM of the p57 peptide (residues 263–285) were restored
(compare lanes 10 and 16). The addition of a 15-mer p57
control peptide corresponding to a region outside the PCNA
binding sequence (residues 303–313), at a concentration of 50
mM, had no detectable effect in the elongation reaction (lane
15). These results demonstrate that the C-terminal domain of
p57 can inhibit PCNA-dependent DNA elongation reactions
catalyzed by the pol d holoenzyme.
Cell Cycle Arrest by p57 C-Terminal Domain Requires
PCNA Binding Activity. To determine whether the p57 C-
terminal domain, when separated from the CDK-cyclin bind-
ing domain, could regulate cell cycle progression in vivo in a
PCNA binding-dependent manner, we cotransfected p57C or
full-length p57 into cultured Saos-2 cells with a plasmid
expressing the green fluorescence protein. At 40 hr posttrans-
fection, transfected cells were analyzed for their DNA content
by flow cytometry. Ectopic expression of full-length p57 and
the C-terminal PCNA binding domains of either p57 or p21,
but not the parental pcDNA3 vector, caused cells to accumu-
late in G1 (Fig. 4A). The mutant p57 (L271AyF275A) that
lacks the ability to bind PCNA did not exhibit any inhibitory
activity, indicating that G1 cell cycle arrest caused by the p57
C-terminal domain is dependent on its PCNA binding activity.
Consistent with its higher affinity for PCNA, the p21 C-
terminal domain was more potent than the p57 C-terminal
FIG. 2. p57 and p21 binds to PCNA via similar sequences. (A) A
small region of human p21 (residues 139–160) sufficient for binding to
PCNA (17–19) contain two critical residues, Met-147 and Phe-150
(boxed), are conserved in both mouse p21 and human p57. Mouse p57
lacks a complete corresponding region and predictably the ability to
bind PCNA. A series of wild-type (residues 263–285) and mutant p57
peptides used in this study are listed. The hp57(BWS8) corresponds to
a mutant p57 identified in a BWS patient (#8) (11). Comparison of
binding between the p57 proteins and PCNA determined from ex-
periments shown in Fig. 2C are shown on the right side and binding
efficiency between wild-type p57 protein and PCNA was set at 100%.
(B) p21 and p57 bind to PCNA via similar sequences. 35S-labeled
PCNA protein (20 ml) was incubated with the various p21 or p57
peptides and then added to an equal amount of GST-p57C or
GST-p21C fusion proteins attached to glutathione-agarose beads.
GST-fusion proteins and bound PCNA were recovered from the
different mixtures and resolved by SDSyPAGE. The gel was stained
with Coomassie blue (Lower) to verify equal recovery of the GST
fusion protein prior to autoradiography (Upper). (C) Mapping of
PCNA binding site in vitro. 35S-labeled PCNA protein (20 ml) was
incubated with 2 mg wild-type or various mutant GST-p57C proteins.
GST-p57C protein and bound PCNA were recovered from the dif-
ferent mixtures and resolved by SDSyPAGE. (D) Mapping of PCNA
binding site in vivo. Yeast HF7c cells were simultaneously transformed
with the parental pGAD or plasmid expressing a GAL4bd fusion
protein with a wild-type or a mutant p57 C-terminal domain and with
a plasmid expressing GAL4ad fusion with PCNA protein. Cells were
streaked on nonselective medium with histidine (-Leu, -Trp) or
selective medium without histidine (-Leu, -Trp, -His).
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domain in causing cell cycle arrest in vivo (Fig. 4A). The
full-length p57 was more potent than the p57 C-terminal
domain in causing G1 arrest, suggesting that PCNA binding
domain contributes only partially to p57’s cell cycle arrest
activity.
Suppression of Cell Transformation by p57 Requires Both
CDK-Cyclin and PCNA Binding Activities. To determine
whether loss of p57’s PCNA inhibitory activity leads to un-
controlled cell growth, we compared the wild-type and PCNA-
binding deficient p57 mutants for their ability to suppress myc
and RAS mediated cell transformation in rat embryo fibro-
blasts. Use of full-length p57 bearing different point mutations
also allowed an assessment of the relative contributions of the
CDKycyclin- and PCNA-binding activities to p57’s function.
Plasmids expressing full-length wild-type p57, p57 mutants
lacking the ability to bind to CDKs and cyclins (p57CKmut), to
PCNA (p57PCNAmut), or the double mutant (p57CKyPCNAmut)
were cotransfected with murine c-myc and an activated
[lVal12]Ha-RAS expression construct into early passage rat
embryo fibroblasts. The impact of each p57 protein on mycy
RAS-mediated cell transformation was assessed by scoring the
number of foci generated (Fig. 4B). In two independent
experiments, expression of wild-type p57 markedly reduced
the number of foci obtained by mycyRAS by '75% (Fig. 4B).
Disruption of either the PCNA binding or the CDKycyclin-
binding activity led to nearly equivalent reductions in p57’s
suppressive potential, suggesting that the CDKycyclin- and
PCNA-binding activities contribute about equally to p57’s in
vivo suppressive function. Loss of both binding functions
completely eliminated p57’s ability to suppress transformation,
as cotransfection of the double mutant with mycyRAS did not
significantly affect the number of foci generated in comparison
to the empty vector control. This result indicates that cell
growth suppression by p57 is primarily dependent on its ability
to bind to CDKycyclin and PCNA and does not involve an as
yet unidentified activity in p57.
DISCUSSION
The presence of separate CDKycyclin and PCNA binding
domains in p21 and the ability of either domain alone to inhibit
the cell cycle has led to the notion that p21 may uniquely
possess two separate activities, each regulating the cell cycle
independently via its own mechanism(s). We show here that in
addition to inhibiting cyclin-CDK enzymes, p57, like p21,
contains a physically separate activity that directly inhibits
PCNA-dependent DNA replication in vitro and prevents cell
entry into S phase in vivo. Therefore, two common structural
and biochemical properties are shared by two members of the
p21 CDK inhibitor family: an N-terminal domain for binding
to CDK-cyclin complexes and a C-terminal domain for binding
to a DNA replication factor, PCNA.
We attribute the partial loss of in vivo cell cycle inhibition by
the mutations in the p57 C-terminal domain, L271A and
F275A, to the disruption of p57’s binding with PCNA. This
interpretation is supported by the observation that mutation of
either residue significantly reduced the binding of p57 with
PCNA, and mutation of both residues almost completely
abolished the binding of p57 to PCNA (Fig. 2). Whether the
loss of p57’s ability to arrest the cell cycle when mutated is
solely due to the loss of its inhibitory activity on the PCNA-
FIG. 3. p57 C-terminal domain mediated inhibition of PCNA-
dependent DNA synthesis by DNA polymerase d. (A) Effects of
full-length CDK inhibitor p21 and the p21 peptide containing the
PCNA binding activity (residues 139–160) on nucleotide incorpora-
tion catalyzed by pol d. (B) Effects of His-p57C and p57 peptide
(residues 263–285) on nucleotide incorporation catalyzed by pol d. (C)
Effects of CDK inhibitors p57 and p21 on the length of the DNA
products formed in the pol d holoenzyme catalyzed reaction. All
reactions contained 5 ng PCNA except lanes 16 and 17 where 50 ng
PCNA protein was added. The levels of inhibitors used were as follows:
lanes 2–4 contained 0.3, 0.12 and 0.06 mM p21, respectively; lanes 5–8,
22.5, 9, 4.5 and 2.25 mM p57C, respectively; lanes 9–12, 16.5, 6.6, 3.3,
and 16.5 mM p57 peptide (residues 263–285), respectively; lanes 13 and
14, 0.8 and 0.075 mM p21 peptide (residues 139–160). Lane 15
contained 50 mM of a p57 peptide corresponding to the last 15 amino
acid residues of human p57 (residues 303–313) outside the conserved
PCNA binding sequence. Lane 16 contained 6.6 mM p57 peptide
(residues 263–285). Lanes 1 and 17 contained no inhibitors. The
reaction described in lane 17 represents the replication activity ob-
served with excess PCNA.
FIG. 4. Inhibition of cell cycle and cell transformation by p57. (A)
Saos-2 cells were transiently transfected with 1 mg of pcDNA3-green
fluorescent protein and 10 mg of indicated plasmids. The percent
distribution in different cell cycle stages was analyzed by flow cytom-
etry. (B) Histogram of the average number of foci per plate counted
12 days posttransfection for two individual experiments combined.
Twelve plates (six for each experiment) that were split 1:3 on the day
following the transfection were counted for each point. Bars 5 SD.
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dependent replication must be interpreted cautiously at
present. Although the C-terminal domain of p57 can inhibit
PCNA-dependent DNA synthesis in vitro (Fig. 3), we have not
determined whether these two mutations may potentially
affect other biological properties of p57 such as CDK-cyclin
binding and cellular localization. In particular, whether loss of
PCNA binding activity may affect p57’s stability is an inter-
esting possibility. Both p21 and p27 are short lived proteins
with estimated half-lives of 30–60 min and are regulated by
ubiquitin-mediated proteolysis (23, 24). Elimination of p27 is
promoted by cyclin E-CDK2 phosphorylation of p27 on T187
whose mutation to alanine created a stable p27 protein and
caused a G1 arrest resistant to cyclin E overexpression (25). p57
is also a short-lived protein and contains a homologous
phosphorylation site, T310, close to the PCNA binding domain
that can be phosphorylated by CDK2 (H.W, and Y.X, unpub-
lished data). It is therefore intriguing to speculate that PCNA
binding may affect, or be affected by, the T310 phosphoryla-
tion that in turn could regulate p57’s degradation by ubiquitin-
mediated proteolysis. This postulation is especially relevant in
light of the fact that we failed in repeated attempts to detect
p57-PCNA complexes by coimmunoprecipitation in mamma-
lian cells despite the presence of readily assembled p57-PCNA
complexes. The possibility that PCNA binding may regulate
p57’s degradation, together with p57’s lower affinity for PCNA
than p21, may provide an explanation for the lack of stable
p57-PCNA complexes in mammalian cells.
The localization of the p57 gene to chromosome 11p15.5, its
genomic imprinting, and its somatic mutations make it a likely
candidate for the tumor suppressor gene postulated to be
present at this locus. Supporting this hypothesis is the obser-
vation that mice lacking p57 function displayed phenotypes
seen in BWS patients (9, 10). The finding that p57 has
PCNA-binding activity at its C terminus whose disruption
resulted in partial reduction of p57’s ability to suppress cell
transformation provides the first evidence that PCNA binding
activity has a distinct role in p57’s function. This finding is
particularly noteworthy in light of recent reports that three of
four p57 mutations identified in BWS patients retained only an
intact N-terminal CDK-cyclin binding domain (11, 12): one
lost the central PAPA repeat and C-terminal domain, and two
contained deletions of the PCNA binding domain (BWS8, and
BWS204, Fig. 2 A). These findings strongly implicate a C-
terminally located function in p57, most likely its PCNA
binding ability, whose disruption may directly contribute to
BWS development.
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